My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

Thermo Fisher Scientific Inc (TMO) — RQD Stock Rating Cockpit

$688.91 -0.55% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $686.92

Thermo Fisher Scientific Inc (TMO) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $255.25B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TMO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TMO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, Thermo Fisher Scientific Inc (NYSE: TMO) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $688.91 (-0.55% 1D, market cap $255.25B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 486 tracked Industrials issuers, TMO ranks #20 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TMO compare to DE and DHR in the Industrials sector?
▼

Within the Industrials sector (Industrial Machinery/Components), TMO carries a Roarable C+ (69/100 RQD), trailing P/E of 39.0x, gross margin of —, and ROIC of 9.3%. By comparison, DE (Deere & Company) holds a C- grade (61/100 RQD, P/E 35.4x, ROIC 9.3%, cap $168.50B) and DHR (Danaher Corporation) posts a C grade (65/100 RQD, P/E 46.1x, ROIC 6.1%, cap $160.08B). Among the 5-stock peer group, ITW leads on earnings multiple (24.3x) while ITW leads on capital efficiency (23.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TMO?
▼

Per TMO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000097745), Thermo Fisher Scientific Inc generated $44.56B in revenue (+3.9% YoY), $6.72B in net income, and $6.29B in free cash flow against $110.34B in total assets and $25.82B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 TMO TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $TMO, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $TMO R/R 2.9 : 1 • RQD 69/100 (C+)
$TMO
Spot $688.91
1. GET IN (ENTRY)
$684.78–$692.35
2. HARD STOP (SUP)
$657.91 (-4.5%)
3. GET OUT (T1/T2)
$742.64 / $779.85
STOP-LOSS FLOOR (SUP $657.91): Hard stop sits 4.5% below spot to cap downside below key institutional support. If $TMO closes a daily candle below $657.91, step aside.
PROFIT TARGETS (RES $742.64 / $779.85): Scale out 50% at T1 (+7.8%) and trail stop to breakeven for T2 (+13.2%).
Want this $TMO sheet + Today's Top 3 Trades emailed free? Paper Trade $TMO →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $TMO Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $686.91 (-0.29%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 14.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C+ · Rk B
Cash (13)Whales (16)SEC (18)Macro (11)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$853 Bull$723 Base$564 Bear
📬 FREE TMO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TMO)Realized 20D OHLCV Swing Band: ±3.8%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY TMO SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 4.50 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)

20D Institutional Volume Accumulation (±3.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Cannibal Buyback (-0.96% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$679.65+5.7% Next Q
Q2 (-2Q)
64
Grade C+$718.64-2.5% Next Q
Q3 (-1Q)
66
Grade B-$700.33-1.6% Next Q
Current
69
Grade C+$688.91+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TMO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, TMO faces multiple-compression risk if 39.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($684.10) or 200D SMA ($562.47) invalidates the momentum regime and cuts Target Base ($723.01) toward Bear Floor ($563.95).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TMO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TMO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
48.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
4.50>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE89% OF RANGE
L: $435$688.91H: $722
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on TMO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

9.3% ROIC with 42.0% gross margin and 2.40% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 4.50 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (63)

27/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like TMO
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (TMO Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TMO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.71%🛡️ HOLDING TREND SUPPORT
2026-11-22O $692.7H $692.7L $688.9C $688.9VOL 1.98M
$741.1$660.5$579.8$499.2$418.6RES $756.3SUP $690.2$688.92026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE NARROW ECONOMIC MOAT (ROIC 9.3% vs WACC 7.3%)

TMO Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $413.95 vs Spot $688.91
MODESTLY OVERVALUED (-66.4%)
Undervalued Zone (< $352) Fair Value Corridor ($352–$476) Overvalued (> $476)
$689
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own TMO Growth & WACC Assumptions

YOUR DCF TARGET
$546.57
5-Yr Annual FCF Growth Rate: 8.9%
Discount Rate (WACC Hurdle): 7.3%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: -66.4% vs $688.91 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TMO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
29.8%/yr Implied 5Y Growth

vs. +3.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TMO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TMO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TMO)

Industrials Rank #20 of 486 ⚔️ DE vs TMO Full Matrix →

1. Head-to-Head Industrials Peer Comparison (TMO vs. DE, DHR, JCI, ITW)

Industry: Industrial Machinery/Components (208 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, Thermo Fisher Scientific Inc (TMO) ranks #20 by composite RQD confidence (69/100, grade C+) and #2 by equity capitalization ($255.25B). Within this direct 5-issuer industry benchmark cohort, ITW leads on earnings valuation at 24.3x trailing P/E, while ITW leads on capital efficiency and profitability with 23.4% ROIC and 52.9% gross margin. ITW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with TMO at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TMO ACTIVE
Thermo Fisher Scientific Inc
C+ 69/100 39.0x — 9.3% -0.55% $255.25B Benchmark Subject
DE
Deere & Company
C- 61/100 35.4x — 9.3% -3.07% $168.50B /de-vs-tmo →
DHR
Danaher Corporation
C 65/100 46.1x 59.1% 6.1% -0.45% $160.08B /dhr-vs-tmo →
JCI
Johnson Controls International plc Ordinary Share
D+ 58/100 29.1x 36.4% 15.6% -1.72% $81.65B /jci-vs-tmo →
ITW
Illinois Tool Works Inc.
B- 71/100 24.3x 52.9% 23.4% -1.88% $78.71B /itw-vs-tmo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000097745 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Thermo Fisher Scientific Inc (TMO) reported GAAP revenue of $44.56B (+3.9% vs. FY2024 revenue of $42.88B , and +4.0% cumulative change since FY2023) , GAAP net income of $6.72B, operating cash flow of $7.82B, and free cash flow of $6.29B (-13.4% YoY). On the balance sheet, TMO closed FY2025 with $110.34B in total assets against $25.82B in total debt (Altman Z-Score: 4.50, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.56B $6.72B $7.82B $6.29B $110.34B $25.82B
FY2024 (FY) 2024-12-31 $42.88B $6.34B $8.67B $7.27B $97.32B $22.77B
FY2023 (FY) 2023-12-31 $42.86B $5.96B $8.41B $6.48B $144.22B $33.75B

3. TMO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TMO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, Thermo Fisher Scientific Inc (NYSE: TMO) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $688.91 (-0.55% 1D, market cap $255.25B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 486 tracked Industrials issuers, TMO ranks #20 in composite RQD confidence.

How does TMO compare to DE and DHR in the Industrials sector?

Within the Industrials sector (Industrial Machinery/Components), TMO carries a Roarable C+ (69/100 RQD), trailing P/E of 39.0x, gross margin of —, and ROIC of 9.3%. By comparison, DE (Deere & Company) holds a C- grade (61/100 RQD, P/E 35.4x, ROIC 9.3%, cap $168.50B) and DHR (Danaher Corporation) posts a C grade (65/100 RQD, P/E 46.1x, ROIC 6.1%, cap $160.08B). Among the 5-stock peer group, ITW leads on earnings multiple (24.3x) while ITW leads on capital efficiency (23.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TMO?

Per TMO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000097745), Thermo Fisher Scientific Inc generated $44.56B in revenue (+3.9% YoY), $6.72B in net income, and $6.29B in free cash flow against $110.34B in total assets and $25.82B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TMO trading relative to its 50-day, 200-day, and 52-week technical levels?

TMO last traded at $688.91 (-0.55% on volume of 1,980,542 shares), positioning the stock +0.70% above its 50-day simple moving average ($684.10) and +22.48% above its 200-day simple moving average ($562.47). Across its 52-week range of $435.27 to $721.64, TMO sits at the 88.6% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±3.8% ($662.73 to $715.09).

ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

TMO — Thermo Fisher Scientific Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Thermo Fisher Scientific Inc (TMO) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $688.91 (-0.55% 1D, market capitalization $255.25B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 9.3%, gross margin of —, operating margin of 17.4%, and free cash flow yield of 2.40%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (18/20): Incorporates a 0.94x equity beta, Altman Z-Score of 4.50, Piotroski F-Score of 8/9, and Debt/Equity of 0.42x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Thermo Fisher Scientific Inc is a NYSE-listed issuer classified in the Industrials sector and Industrial Machinery/Components industry. The company operates a sterile fill-finish business within its Biopharma Services segment, which the source links to Eli Lilly's GLP-1 manufacturing needs. FY 2025 revenue was $44.56B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Thermo Fisher Scientific Inc (TMO) reported $44.56B in annual revenue (up from $42.88B in FY2024, +3.9% YoY) and $6.72B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.86B revenue, $5.96B net income) through FY2025, TMO scaled operating cash flow to $7.82B and free cash flow to $6.29B, backed by $110.34B in total assets against $25.82B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $435.27 – $721.64 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 39.0x trailing P/E and 30.4x EV/EBITDA against 17.4% operating margins and a 0.94x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

TMO's principal upstream-to-downstream dependency is in sterile fill-finish: capacity constraints at contract manufacturing sites flow through to GLP-1 drug makers such as Eli Lilly. The investor implication is a second-order bottleneck dynamic: if validation timelines for new lines are long (18–36 months), near-term capacity remains tight and supports pricing and volume for incumbents, but the same timeline means any shortfall in capacity is slow to correct. The competing explanation, that a large drug maker internalizes fill-finish, is the main second-order risk, because it would redirect volume away from TMO over time.94.

  • Key Question #1: Can TMO sustain or expand its 17.4% operating margin and 9.3% ROIC against Industrial Machinery/Components peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $44.56B and free cash flow of $6.29B, how will capital allocation balance growth reinvestment against $25.82B in total debt?
  • Key Question #3: How sensitive is TMO's 36.3x forward P/E multiple to Industrials capital spending cycles and macro interest-rate shifts (Beta 0.94x)?

TMO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Thermo Fisher Scientific Inc (TMO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TMO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TMO Bull vs. Bear Conversation Board — What's Your Call at $688.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TMO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TMO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $843.37 (+21.0%)
📌 Pinned Debate

Balance-sheet strength (Piotroski F 8/9, Altman Z 4.5) and strong institutional accumulation (19/20 whale pillar) underpin a Roarable B

Balance-sheet strength (Piotroski F 8/9, Altman Z 4.5) and strong institutional accumulation (19/20 whale pillar) underpin a Roarable Buy rating.. When you look under the hood at TMO, Fundamental Cash Engine is 13/20 with 0.0% gross margins and 9.3% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (19/20) has been quietly accumulating below $711.85. My 12M target is $843.37.

VolSurface_Trader 🐂 BULL

Both sides have a point here — TMO's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $564.57 (-19.0%)
Spot @ $697.00

A P/E (TTM) of 39 and an FCF yield of 2.4% leave little valuation cushion if sterile fill-finish demand from GLP-1 customers normalizes

Careful chasing TMO at $697.00. A P/E (TTM) of 39 and an FCF yield of 2.4% leave little valuation cushion if sterile fill-finish demand from GLP-1 customers normalizes or is internalized.. Gross margin is 0.0%, but operating margin is 17.4%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $564.57 on multiple compression.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE